Cemiplimab 350 mg IV

DRUG2 trials

Sponsors

Gruppo Oncologico Italiano di Ricerca Clinica, The Netherlands Cancer Institute

Conditions

Advanced Squamous Non-Small Cell Lung CancerImmunotherapyNon Small Cell Lung Cancer

Phase 2

A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer

Not yet recruitingNCT07418931

Gruppo Oncologico Italiano di Ricerca ClinicaAdvanced Squamous Non-Small Cell Lung Cancer

Start: 2026-05-01End: 2030-11-01Target: 108Updated: 2026-02-18

RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer

Not yet recruitingNCT07808138

The Netherlands Cancer InstituteImmunotherapy, Non Small Cell Lung Cancer

Start: 2026-11-01End: 2029-12-01Target: 30Updated: 2026-09-08